Health Care Spending Associated With Preventative Pharmacologic Therapy for Urolithiasis
Authors:
- 1 September 2025
- journal article
- Published by Wolters Kluwer Health in Urology Practice
- Vol. 12 (5) , 594-602
Abstract
Urolithiasis is among the most expensive urologic conditions from a payer standpoint. Preventative pharmacologic therapy (PPT) can reduce symptomatic recurrences, however, the potential savings from fewer recurrences may be offset by medication costs. This study aimed to evaluate the cost of PPT from the payer perspective. The Medicare-Litholink database was queried for beneficiaries with urolithiasis who had at least one urinary chemistry abnormality. Payments made on their behalf, along with out-of-pocket costs were measured. Payments were compared among amongst three groups using two-part generalized linear models: patients prescribed guideline-concordant PPT who adhered to therapy, those prescribed PPT but did not adhere, and untreated patients. Among 16,329 patients who met inclusion criteria, 30.8% were prescribed PPT. Alkali therapy represented 42.7% of all spending among adherent patients, whereas thiazides and uric acid reducing therapies combined contributed only 3.3%. Out-of-pocket spending on alkali represented 88% of total prescription costs for adherent patients. For patients with hypocitraturia or low pH, adherence to therapy resulted in the lowest mean cost for symptomatic stone events but the highest overall costs due to medication expenses. Conversely, in hypercalciuria and hyperuricosuria, non-adherent patients were the most expensive overall even after multivariable adjustment. Among patients with hypocitraturia and low pH, adherence was the most expensive, driven by medication costs. Conversely, amongst patients with hypercalciuria and hyperuricosuria, non-adherence was costliest. Although PPT can lead to reduced costs due to averted stone events, medication adherence is critical to ensuring these savings are fully realized.Keywords
This publication has 26 references indexed in Scilit:
- Medical Management of Kidney Stones: AUA GuidelineJournal of Urology, 2014
- Medical Management to Prevent Recurrent Nephrolithiasis in Adults: A Systematic Review for an American College of Physicians Clinical GuidelineAnnals of Internal Medicine, 2013
- Prevalence of Kidney Stones in the United StatesEuropean Urology, 2012
- Measuring concurrent adherence to multiple related medications.2009
- Direct and indirect costs of nephrolithiasis in an employed population: Opportunity for disease management?Kidney International, 2005
- POTASSIUM-MAGNESIUM CITRATE IS AN EFFECTIVE PROPHYLAXIS AGAINST RECURRENT CALCIUM OXALATE NEPHROLITHIASISJournal of Urology, 1997
- Randomized Double-Blind Study of Potassium Citrate in Idiopathic Hypocitraturic Calcium NephrolithiasisJournal of Urology, 1993
- The First Kidney StoneAnnals of Internal Medicine, 1989
- Randomized Trial of Allopurinol in the Prevention of Calcium Oxalate CalculiNew England Journal of Medicine, 1986
- Placebo Versus Allopurinol for Renal CalculiJournal of Urology, 1977